Arcus Biosciences Presents Phase 1 Data for AB928 in Healthy Volunteers at 2018 AACR Annual Meeting
Arcus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.
AB154 is a monoclonal antibody (mAb) that potently and selectively blocks a novel immune checkpoint called TIGIT.
AB122 is a monoclonal antibody (mAb) that potently and selectively blocks a protein called PD-1.
AB680 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine.